Osimertinib, an irreversible EGFR-TKI, in relapsed EGFR-mutated non-small cell lung cancer patients previously treated with an EGFR-TKI, coupled to extensive translational studies

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Mar 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Osimertinib (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms TREM

27 Mar 2023 Planned End Date changed from 1 Dec 2021 to 1 Jun 2023.
27 Mar 2023 Planned primary completion date changed from 1 Jan 2021 to 1 Jun 2023.
09 Aug 2022 Plasma samples of 20 patients from this study was used to analyze exosomal RNAs, presented at the 2022 World Conference on Lung Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com